Human Papillomavirus (HPV) Guidelines

Updated: Feb 05, 2019
  • Author: Peter A Gearhart, MD; Chief Editor: Pranatharthi Haran Chandrasekar, MBBS, MD  more...
  • Print

Guidelines on Human Papillomavirus Vaccination by the American Cancer Society

Guidelines on human papillomavirus vaccination by the American Cancer Society (ACS) are as follows: [113]

  • The ACS recommends that all girls and boys aged 11-12 years receive the HPV vaccine.
  • The HPV vaccination series can be started at age 9 years.
  • The vaccination series should be completed by age 13 years to increase effectiveness; late vaccination should be completed as soon as possible.
  • Vaccination should occur in females aged 13-26 years and males aged 13-21 years who have not been previously vaccinated or who have not completed the 3-dose series. Men aged 22-26 years may also be vaccinated.
  • Vaccination is recommended though age 26 years in men who have sex with men and in immunocompromised individuals, including those with HIV infection, if not previously vaccinated.
  • Patients aged 22-26 years who have not received the vaccine or have not completed the series should be advised that the vaccine becomes less effective at lowering cancer risk at older ages.
  • HPV vaccination should be given along with other routine adolescent vaccines, such as Tdap and MCV4.
  • Females can receive vaccination with the 9vHPV vaccine. The bivalent (2vHPV) and quadrivalent (4vHPV) are no longer marketed in the United States.
  • Males can receive vaccination with the 9vHPV vaccine. The quadrivalent (4vHPV) is no longer marketed in the United States.

Advisory Committee on Immunization Practices Guidelines on Human Papillomavirus Vaccination

The following are the Advisory Committee on Immunization Practices (ACIP) guidelines on human papillomavirus vaccination: [114]

  • Children and adolescents aged 15 years and younger need just 2, not 3, doses of HPV vaccine, which is recommended because of the vaccine's enhanced immunogenicity in preteens and adolescents aged 9-14 years.
  • Efficacy trials showed that the response in younger children after 2 doses is as good as or better than the response after 3 doses in older teens and young adults.
  • In addition to dropping the third dose for younger-than-15-years age group, the recommendation expands the time interval from the first to the second dose from 1-2 months to 6-12 months.
  • The schedule for older adolescents and young adults aged 15-26 years remains the same, at 3 inoculations within 6 months.